What Кардосал 40 treats: Main Uses and Benefits

This drug is primarily used to address the chronic condition of elevated blood pressure, a symptom related to systemic imbalance, in adults and children aged 6 to 16 years. The drug is indicated for managing essential hypertension, whether used alone for initial support or in combination with other agents. The goal of use is to help achieve and support consistent blood pressure reduction, which generally supports long-term health.

The medication is relevant in clinical settings associated with heightened cardiovascular risk factors, and its use is considered appropriate across conditions involving systemic or localized discomfort stemming from high pressure. The drug is relevant in conditions such as hypertension, and its use may be part of a supportive strategy for managing associated risk factors in patients, for example, those with diabetes.

Key Focus: Supportive Cardiovascular Management

• Quick Fact: Supportive Cardiovascular Management The medication assists with maintaining functional stability by supporting the reduction of physiological strain on organs such as the heart, brain, and kidneys. This management strategy is relevant in clinical settings associated with heightened cardiovascular risk factors.

The regulatory eligibility for Кардосал 40 (Olmesartan Medoxomil) is strictly defined by official criteria covering age, reproductive status, and specific comorbidities, determining who is permitted to use the medicine.

Eligibility Status	Populations / Conditions Defined by Regulators
Approved Use	Adults and Pediatric patients aged 6 to 16 years.
Absolute Contraindication	Pregnant women, infants (children younger than 1 year), hypersensitivity to components, and patients with diabetes receiving aliskiren.
Use Not Recommended	Patients with severe renal impairment or severe hepatic impairment.

Age-Related Eligibility: Use is strictly prohibited in infants under one year. For children aged one to under six, safety and effectiveness are officially not established in regulatory documentation.

Eligibility Restrictions: Patients who are volume- or salt-depleted must initiate treatment under close medical supervision. For nursing mothers, the official label requires a decision to discontinue either the drug or nursing. These statements clearly establish the constraints on who is permitted to use the medicine.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Кардосал 40 (Olmesartan Medoxomil), reflecting regulatory information from government health authorities. These interactions are classified based on the effects observed during co-administration.

Contraindicated Combinations and High-Risk Interactions

Co-administration with Aliskiren is contraindicated in patients diagnosed with diabetes mellitus or with renal impairment (Glomerular Filtration Rate < 60 ml/min/1.73 m2). This restriction is due to an increased risk of hypotension, hyperkalemia, and decreased renal function.

Pharmacodynamic and Exposure-Modifying Interactions

• Dual Blockade of the Renin-Angiotensin System (RAS): Co-administration with other RAS blocking agents, such as ACE inhibitors or other ARBs, is associated with increased risks of hypotension and hyperkalemia.
• Potassium-Altering Agents: Agents that increase serum potassium, including potassium-sparing diuretics and potassium supplements, may lead to increased risk of hyperkalemia.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): These agents can attenuate (reduce) the antihypertensive effect of Olmesartan Medoxomil and may cause reversible deterioration of renal function, particularly in the elderly or volume-depleted patients.
• Lithium: Concomitant use with Olmesartan Medoxomil may cause increases in serum lithium concentrations and the risk of lithium toxicity.

Timing-Based Administration Requirements

• Colesevelam Hydrochloride: To mitigate the reduction in Olmesartan systemic exposure, administration of Olmesartan Medoxomil should be considered at least 4 hours before the dose of Colesevelam Hydrochloride.

Кардосал 40 is a drug formulation containing the prodrug olmesartan medoxomil. Following oral administration, the ester prodrug is rapidly and completely hydrolyzed in the gastrointestinal tract to its biologically active compound, olmesartan. Olmesartan functions as a non-peptide, competitive angiotensin II receptor blocker (ARB).

It targets the Angiotensin II type 1 (AT1) receptors located on vascular smooth muscle, adrenal glands, and other tissues. Olmesartan acts as a selective antagonist at the AT1 receptor, exhibiting a significantly higher binding affinity for the AT1 subtype than the AT2 subtype. By blocking the binding of the endogenous hormone angiotensin II to the AT1 receptor, the drug prevents the receptor-mediated intracellular signaling cascades. Downstream consequences of AT1 blockade include the inhibition of vasoconstriction in arterioles and the suppression of aldosterone release from the adrenal cortex. The system-level physiological modulation involves a reduction in total peripheral vascular resistance due to vasodilation, coupled with a decrease in sodium and water retention via reduced aldosterone effects on the renal distal convoluted tubule and collecting duct. This ultimately leads to a sustained modulation of systemic arterial pressure.

Administration Guidelines for Кардосал 40

The administration of Кардосал 40 (Olmesartan Medoxomil) follows established patterns which define the precise route, frequency, and dosage patterns for use in the management of high blood pressure.

---

Administration Scope

The medicine is intended for oral administration as a tablet. The tablet should be swallowed whole with a sufficient amount of fluid, and it must not be chewed. Administration is once daily, and the tablet can be taken with or without food, allowing flexibility within the daily routine.

---

Labeled Dosing Regimens

Category	Instruction
Adult Starting Dose	20 mg once daily.
Maintenance Range	20 mg to 40 mg once daily.
Adult Maximum Dose	40 mg once daily.
Titration Interval	Dose adjustment, if required, should occur after a minimum of two weeks of therapy.

---

Population-Specific Use

Modified use applies to specific populations. For patients with mild-to-moderate renal or moderate hepatic impairment, the maximum daily dose is restricted to 20 mg. Dosing for pediatric patients (6 to <18 years) is weight-dependent, with specific starting and maximum doses based on whether the child weighs above or below 35 kg. Standard procedure for a missed dose involves taking the dose as soon as it is remembered, unless it is almost time for the next scheduled dose; in this case, the missed dose is skipped, and the regular schedule is resumed without doubling the intake.

This protocol involves adherence to specific dose limits and timing rules, structuring the medicine's long-term use.

Cardosal 40: Recent Clinical Evidence

Recent clinical research has focused on the efficacy and safety profile of Cardosal 40 (Aprovel's trade name, containing irbesartan) in managing hypertension (high blood pressure). Evidence from large-scale, controlled studies supports its role as an angiotensin II receptor blocker (ARB), examining its effects on lowering blood pressure and reducing associated risks.

Efficacy in Blood Pressure Reduction

Studies involving patients with essential hypertension have examined the blood pressure-lowering effect of the 40 mg dose. Results indicate that the administration of irbesartan at this dosage is associated with statistically significant reductions in both systolic blood pressure (SBP) and diastolic blood pressure (DBP) over a 24-hour period. Clinical trials generally show that the peak effect is achieved within 3 to 6 hours after dosing.

Studies on Organ Protection

Research has specifically investigated the potential role of irbesartan in renal (kidney) protection in patients who have hypertension and Type 2 diabetes mellitus. Findings from large, long-term trials have observed that this medication may be associated with a reduced risk of developing overt nephropathy (kidney damage) and a slowing of the decline in glomerular filtration rate (GFR) compared to placebo in this specific patient population.

Safety and Tolerability

Clinical data indicates that irbesartan is generally well-tolerated across different age groups. The most commonly reported adverse events in studies were mild to moderate, including headache, dizziness, and fatigue. The incidence of serious side effects, such as angioedema, was reported as low in the trial populations.

Key Studies & References Effect of Irbesartan on the Development of Overt Nephropathy in Patients with Type 2 Diabetes

Common questions about Кардосал 40 (FAQ)

Q: Can Кардосал 40 be used for conditions other than hypertension?

Official regulatory documents state that this medication is indicated solely for the management of high blood pressure (hypertension). Its official authorization by regulatory bodies is based on its established efficacy in consistently lowering blood pressure levels. Use for any condition other than its approved indication is considered off-label.

Q: Is swelling (edema) listed as a potential side effect of Кардосал 40?

Official safety information does list a rare but serious form of swelling called angioedema, which involves deeper layers of the skin, potentially affecting the face or throat. The potential for angioedema is a key safety note in the regulatory information. General swelling of the limbs (peripheral edema) is not typically highlighted as a common effect in the monotherapy labeling.

Q: Is dry cough associated with the use of Кардосал 40?

Dry cough is generally not listed among the commonly reported side effects in the official product information for this medicine. As an Angiotensin II Receptor Blocker (ARB), its mechanism of action is different from the older class of medicines (ACE inhibitors) often linked to causing a cough.

Q: What is described in official sources regarding the use of alcohol while taking Кардосал 40?

Regulatory information notes that alcohol may have an additive effect in lowering blood pressure. This combined effect can increase the likelihood of experiencing low blood pressure symptoms. These effects can include dizziness, lightheadedness, or fainting.

Q: What non-directive information is available about the preferred timing of taking Кардосал 40?

The official guidelines state that the tablet should be taken once daily. For best consistency of the medicine in the blood, it is described in the guidelines to take it at the same time each day. It is also stated that the tablet can be taken either with or without food.

Q: Is there a generic version of Кардосал 40 currently available?

Yes, the active substance, Olmesartan Medoxomil, is available as a generic version. Generic medications contain the same active ingredient and are required by regulatory bodies to have the same clinical effect as the original branded product.

Q: Is there a risk of withdrawal effects mentioned if the use of Кардосал 40 is discontinued suddenly?

Clinical studies have investigated this concern and found no evidence of a rebound effect after abruptly stopping the medicine following long-term use. A rebound effect is defined as a sudden and sharp return to dangerously high blood pressure levels.

Q: Does official safety information mention any known issues related to fertility and Кардосал 40 use?

The official labeling generally does not include specific statements regarding effects on male or female fertility. However, the documentation emphasizes the risk of injury and death to a developing fetus if the medicine is used during the second and third trimesters of pregnancy.

Q: Can Кардосал 40 cause increased sensitivity to sunlight?

While not highlighted as a frequent side effect of this specific medicine, photosensitivity (increased skin sensitivity to the sun) has been reported in post-marketing surveillance. This effect is associated with medicines belonging to the Angiotensin II Receptor Blocker (ARB) class.

Q: What is the half-life of the active ingredient in Кардосал 40, as described in pharmacokinetics data?

Pharmacokinetics data from regulatory documents show that the active substance, Olmesartan, has an elimination half-life of approximately 13 hours. This figure describes the time it takes for half of the substance to be eliminated from the body.

Storage and Disposal of Кардосал 40

The storage of Кардосал 40 (olmesartan medoxomil) tablets must adhere strictly to labeled conditions to ensure product quality.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at 20°C to 25°C (68°F to 77°F), with permitted excursions between 15°C and 30°C.
Protection	Keep the product protected from moisture and excess heat.
Container	Keep the medication in the original container, tightly closed.

The medication must always be stored out of the sight and reach of children, and safety caps must be kept locked.

Disposal Instructions

Unused or expired product should be disposed of in accordance with local, regional, or national regulations. If a drug take-back program is unavailable, government guidelines recommend mixing the medicine with an undesirable substance before sealing it in a container and discarding it in the household trash.